论文部分内容阅读
目的探讨PTEN、bcl-2、P53表达在肺神经内分泌癌中临床病理意义。方法选择我院2012年1月~2014年1月收治的肺神经内分泌癌患者52例作为研究对象,采用免疫组织化学SP法检测PTEN、bcl-2、P53在肺神经内分泌癌中的表达情况,并与正常肺组织的表达情况进行对照分析。结果肺神经内分泌癌组织的PTEN、bcl-2、P53表达阳性率分别为36.5%、23.1%、48.1%,而正常肺组织PTEN、bcl-2、P53表达阳性率分别为71.2%、3.8%、19.2%,两组间差异均具有显著性(P<0.05)。结论 PTEN、bcl-2、P53表达在肺神经内分泌癌发生、发展中起到重要作用,可以作为临床诊治肺神经内分泌癌的参考指标。
Objective To investigate the clinicopathological significance of PTEN, bcl-2 and P53 expression in pulmonary neuroendocrine carcinoma. Methods 52 patients with neuroendocrine carcinoma in our hospital from January 2012 to January 2014 were selected as the research objects. The expression of PTEN, bcl-2 and P53 in pulmonary neuroendocrine carcinoma was detected by immunohistochemical SP method. And compared with the normal lung tissue expression analysis. Results The positive rates of PTEN, bcl-2 and P53 expression in pulmonary neuroendocrine carcinoma were 36.5%, 23.1% and 48.1% respectively, while the positive rates of PTEN, bcl-2 and P53 in normal lung tissues were 71.2%, 3.8% 19.2%, the differences between the two groups were significant (P <0.05). Conclusions The expression of PTEN, bcl-2 and P53 plays an important role in the occurrence and development of pulmonary neuroendocrine carcinoma and may serve as a reference index for clinical diagnosis and treatment of pulmonary neuroendocrine carcinoma.